Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ryan Confer
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 13
- Beta
- -0.89
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -16.28
Financials
Net Income
$-4.45MEBITDA
$-4.45MFree Cash Flow
$-5.14MEPS (diluted)
$-9.40Shares Outstanding (diluted)
473.2K+43630.3%Operating Expenses
$4.48MCash & Debt
$15.15MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-16.23M | $-382.80 |
| 2024 | $0.00 | $-21.11M | $-5872.98 |
| 2023 | $0.00 | $-30.86M | $-24838.00 |
| 2022 | $0.00 | $-23.74M | $-21780.00 |
| 2021 | $0.00 | $-20.66M | $-19305.00 |
| 2020 | $0.00 | $-17.94M | $-22198.00 |
| 2019 | $0.00 | $-10.65M | $-29304.00 |
| 2018 | $0.00 | $-12.37M | $-39567.00 |
| 2017 | $0.00 | $-3.31M | $-12705.00 |
| 2016 | $0.00 | $-4.13M | $-16830.00 |
| 2015 | $0.00 | $-1.07M | $-25575.00 |
Valuation
GNPXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80Social Signal Score
Mentions (1)
- Newsprnewswire.com·1d ago·Negative
…sses for IND-Enabling Preclinical Studies and Future Clinical Trials AUSTIN, Texas, Aug. 18, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has entered into a development and manufacturing agreement with a leading U.S. based clinical and commercial Contract Development and Manufacturing Organization (CDMO) to initiate …
View source ↗
Earnings
Wed, Dec 2(in 3 months)
Typical surprise -411.3% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Mar 30$-25.30 vs $-286.00beat
- Fri, Nov 14$-109.89 vs $-275.00beat
- Fri, Aug 8$-187.00 vs $-15.62miss
- Mon, May 12$-285.71 vs $-55.88miss
- Tue, Apr 1$-462.00 vs $-18.04miss
Estimates and results for GNPX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by GNPX officers and directors.
- Bought
- $107k
- Sold
- $22
5 trades
2 trades
- Longnecker Brent Msold
- Longnecker Brent Msold
- Varner John Rodneybought
- Vaczy Catherine Mbought
- Longnecker Brent Mbought
- Varner John Rodneybought
- Pham Julien Lbought
93 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.